Multilayer-strategy to enhance optimal safety of the blood supply: The role of pathogen inactivation for optimizing recipient safety and helping health care cost containment: Moderator views.
This brief paper is based on the Coimbra 'conference presentation by the moderator', prior to the two main lectures on pathogen reduction treatment [PRT] of plasma. Being an educationist and teacher in core and having a great interest to simplify the message convey to conference' participants and readers I decided to maintain the slide format of the presentation. To highlight most effectively the role played by pathogen reduction to supplement the multilayer-strategy already in place, emphasizes were placed by going back to basic focusing on: where we were, where we are now and where we are going!. The unresolved problems of viral safety of blood components and criteria of universal acceptability of PRT are highlighted so is the need for further DDR strategies both in incremental and innovative ways. Finally the issue of who would benefit from implementation of PRT is described based on published data and also providing some visionary foresights for the long term benefits of PRT in both optimizing the safety of blood supply and helping at least in health care containment. I hope this new approach will be useful to readers, providing at least some conceptual and technical supports in understanding the role of PRT in optimizing the safety of blood supply.
International Consultancy in Blood Components Quality/Safety Improvement, Audit/Inspection and DDR Strategy, London, UK. Electronic address: jseghatchian@btopenworld.com.
Jerard
J
Seghatchian
D001424:Bacterial Infections / Q000517:prevention & control / Q000635:transmission; D001771:Blood Banks / Q000592:standards*; D016913:Blood Component Transfusion / Q000379:methods / Q000592:standards*; D001782:Blood Donors; D001793:Blood Preservation; D058731:Blood Safety / Q000379:methods*; D017848:Blood-Borne Pathogens; D003363:Cost Control; D004203:Disinfection; D046148:Donor Selection; D006801:Humans; D008297:Male; D061214:Patient Safety; D017096:Prion Diseases / Q000517:prevention & control / Q000635:transmission; D016730:Program Development; D014777:Virus Diseases / Q000517:prevention & control / Q000635:transmission
Blood safety; Prion removal; bacterial prevention; cost containment, health care cost; criteria of acceptability; immunomodulations; microvesicule/BRM; pathogen inactivation/reduction; transfusion science/medicine